Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
about
Polychromatic flow cytometry in evaluating rheumatic disease patientsRituximab in diffuse cutaneous systemic sclerosis: should we be using it today?Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyComparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor HScleroderma renal crisis: a pathology perspectiveCoagulation and autoimmunity in scleroderma interstitial lung disease.Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequencyMultifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosineUpdate on pathophysiology of scleroderma with special reference to immunoinflammatory events.Multiple paths to loss of anergy and gain of autoimmunity.B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosisCirculating biomarkers of interstitial lung disease in systemic sclerosis.Abnormal B lymphocyte activation and function in systemic sclerosis.B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.Challenges and opportunities in treating inflammation associated with pulmonary hypertension.Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma.B cell block: is rituximab a new possible treatment for systemic sclerosis?BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians.B cells: no longer bystanders in liver fibrosis.B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence.Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.Prevalence of HLA DQB1*0602 allele in patients with migraine.Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.Editorial: Bench to Bedside-and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe.PKK deficiency in B cells prevents lupus development in Sle lupus mice.Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts.Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab.Evaluation of membrane-bound and soluble forms of HLA-G in Systemic Sclerosis.Características de atividade das células natural killer em pacientes com esclerose sistêmica
P2860
Q26827075-2C1ABC39-5B81-41BF-8E15-CF119F2841AEQ27022117-A1B0BED2-BCE4-4CA8-ADC3-D678E556E59BQ33588875-64999D6A-1264-457B-83E3-13E297C0DBCAQ33668640-87D1DCFF-61CD-4D98-A4E8-FB9821DD656FQ34218928-E6AF0564-B8C5-491D-ABBE-A6D3DD3E9923Q34770486-DA115252-DEDC-4B83-9B04-A65B296283C0Q35637803-B4C87C32-03C5-4473-9BA4-095FFDEF8945Q35954658-0A876AE2-BB65-4281-B068-69686EC3851BQ36371453-6F1B2A8C-6BD8-4898-BE81-18CAABCC53A4Q36691117-3F722506-E62B-40FB-80E5-2348AE72C0FDQ36691126-4DFB584F-17F2-4DEA-A28A-083AA7F8DFF3Q36761364-4F1B846C-FBFF-44EF-85D2-CBD6AD6C4966Q36922982-ED7BFA9A-3A79-4D9F-AC62-7026072BAA52Q36924505-2C0EE877-A4A9-4470-961C-BDC8CA540569Q36975931-1766C9A7-2AF8-46D0-926F-DD52F6A2B6CEQ37690672-006E2C00-9C03-4E27-A0D2-D50DF649CCCFQ38044387-0218C82B-3605-42C4-8B5A-47C20F21508EQ38352418-5CDAC8E2-0F18-460C-BD15-878FFFC84830Q38701988-66A87940-30AA-4664-A2B0-CDA5351D52FAQ38812727-2F11B3AB-A46E-4EB3-B9A7-2AE13FCFBA52Q40321155-99E484C8-975B-444D-A77F-E09D4B33A37FQ41497095-661220B0-C169-43A0-A5A0-3108166CC7CBQ41886328-FCAA25A5-9C29-4475-8A14-582662DC6660Q42094448-DDC48EE9-1428-42F7-AD2D-F46AF59B9513Q42771422-52CF63E8-052B-4C01-A3BB-302BE5083C37Q42855117-14470D66-F4B8-4E39-8411-A21CD7DC6139Q46491430-CA9B2318-89C9-43BC-B6FA-A5C89A7A21A0Q46698023-15F90EDC-844C-4EE9-8F34-DDBF3F925BC6Q47777296-F986DF13-9689-47B0-9D44-F962A3CF53E1Q50091398-22A6DB4F-7A7D-42DE-82A7-1B7E7734A70FQ50678340-DA8CBF2D-53E2-4F6B-A9E8-858AE6C9C3DBQ51250934-DD3458D3-F423-47DC-8F84-C827E0448465Q51593209-D71563D4-3D6E-4E54-BDF6-8BA503FB983CQ52320287-0325CE72-DD16-4CB9-BE81-1969DE1E7143Q57987457-6A5697F6-64E0-48F6-903E-C9CF264393A2
P2860
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
@ast
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
@en
type
label
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
@ast
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
@en
prefLabel
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
@ast
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
@en
P2093
P1433
P1476
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
@en
P2093
Kazuhiko Takehara
Manabu Fujimoto
Minoru Hasegawa
Shinichi Sato
Thomas F Tedder
P304
P356
10.1016/J.MOLIMM.2004.06.025
P577
2004-11-01T00:00:00Z